A multiple sclerosis disease progression measure based on cumulative disability

被引:2
|
作者
Manouchehrinia, Ali [1 ]
Kingwell, Elaine [2 ,3 ]
Zhu, Feng [2 ,3 ]
Tremlett, Helen [2 ,3 ]
Hillert, Jan [1 ]
Ramanujam, Ryan [1 ,4 ]
机构
[1] Karolinska Inst, Karolinska Univ Hosp Solna, Dept Clin Neurosci, Stockholm, Sweden
[2] Univ British Columbia, UBC Hosp, Fac Med Neurol, Vancouver, BC, Canada
[3] Univ British Columbia, Djavad Mowafaghian Ctr Brain Hlth, Vancouver, BC, Canada
[4] Royal Inst Technol, Dept Math, Stockholm, Sweden
基金
加拿大健康研究院;
关键词
Multiple sclerosis; progression measure; outcome; disability;
D O I
10.1177/1352458520988632
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Existing severity measurements in multiple sclerosis (MS) are often cross-sectional, making longitudinal comparisons of disease course between individuals difficult. Objective: The objective of this study is to create a severity metric that can reliably summarize a patient's disease course. Methods: We developed the nARMSS - normalized ARMSS (age-related MS severity score) over follow-up, using the deviation of individual ARMSS scores from the expected value and integrated over the corresponding time period. The nARMSS scales from -5 to +5; a positive value indicates a more severe disease course for a patient when compared to other patients with similar disease timings. Results: Using Swedish MS registry data, the nARMSS was tested using data at 2 and 4 years of follow-up to predict the most severe quartile during the subsequent period up to 10 years total follow-up. The metric used was area under the curve of the receiver operating characteristic (AUC-ROC). This resulted in measurements of 0.929 and 0.941. In an external Canadian validation cohort, the equivalent AUC-ROCs were 0.901 and 0.908. Conclusion: The nARMSS provides a reliable, generalizable and easily measurable metric which makes longitudinal comparison of disease course between individuals feasible.
引用
收藏
页码:1875 / 1883
页数:9
相关论文
共 50 条
  • [1] A multiple sclerosis disease progression measure based on rate of cumulative disability
    Manouchehrinia, A.
    Hillert, J.
    Ramanujam, R.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 79 - 80
  • [2] Is the current trial definition of confirmed disability progression in multiple sclerosis an accurate measure of permanent disease progression?
    Butzkueven, H.
    Mechati, S.
    Hoffmann, M.
    Arruda, W. O.
    Bacile, E.
    Boz, C.
    Caride, A.
    Chapman, J.
    Charest, S.
    Cristiano, E.
    Deri, N.
    Duquette, P.
    Fiol, M.
    Flechter, S.
    Ginestal, R.
    Giuliani, G.
    Grammond, P.
    Grand' Maison, F.
    Izquierdo, G.
    Kappos, L.
    Karussis, D.
    Lechner-Scott, J.
    Melcon, M.
    Naegelin, Y.
    Paine, M.
    Petersen, T.
    Poehlau, D.
    Rodriguez Alfici, A.
    Santiago, V.
    Savino, A.
    Timmermans, B.
    Trojano, M.
    Turk Boru, U.
    Ucles, A.
    Verheul, F.
    Jolley, D.
    MULTIPLE SCLEROSIS, 2006, 12 : S5 - S5
  • [3] Trial-defined disease progression in multiple sclerosis is a poor measure of permanent disability progression.
    Butzkueven, Helmut
    Mechati, Samir
    Hoffmann, Michelle W.
    Arruda, Walter
    Boz, Cavit
    Bacile, Elizabeth
    Caride, Alejandro
    Chapman, Joab
    Charest, Stephane
    Cristiano, Edgardo
    Deri, Norma
    Duquette, Pierre
    Fiol, Marcela
    Flechter, Shlomo
    Ginestal, Ricardo
    Giuliani, Giorgio
    Taffi, Ruja
    Grammond, Pierre
    Grand-Maison, Francois
    Izquierdo, Guillermo
    Kappos, Ludwig
    Karussis, Dimitrios
    Melcon, Mario
    Naegelin, Yvonne
    Paine, Mark
    Petersen, Thor
    Poehlau, Dieter
    Rodriguez, Alberto
    Santiago, Vetere
    Savino, Aldo
    Timmermans, Bertine
    Trojano, Maria
    Boru, Ulku Turk
    Ucles, Antonio
    Verheul, Freek
    Jolley, Damien
    NEUROLOGY, 2007, 68 (12) : A165 - A165
  • [4] Sustained decrease of income in multiple sclerosis: a new possible disability outcome measure of disease progression
    Christakou, A. E.
    He, A.
    Stawiarz, L.
    Spelman, T.
    Manouchehrinia, A.
    Friberg, E.
    Glaser, A.
    Hillert, J.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 486 - 487
  • [5] A Composite Measure of Multiple Sclerosis Disease Progression in AFFIRM
    Zhang, Annie
    Pace, Amy
    Hotermans, Christophe
    Hyde, Robert
    NEUROLOGY, 2011, 76 (09) : A603 - A604
  • [6] Multiple Sclerosis, disability and progression in Pakistan
    Wasay, M.
    Khatri, I.
    Jabeen, K.
    Ali, S.
    Subhan, M.
    Shahbaz, N.
    Ahmed, A.
    Khoso, N.
    Asif, A.
    Fredrikson, S.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2009, 285 : S196 - S196
  • [7] Measuring disability progression in multiple sclerosis
    Achiron, Anat
    JOURNAL OF NEUROLOGY, 2006, 253 (Suppl 6) : 31 - 36
  • [8] Smoking and disability progression in multiple sclerosis
    Hedstrom, Anna Karin
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2020, 20 (08) : 739 - 741
  • [9] Disability progression in aggressive multiple sclerosis
    Menon, Suresh
    Zhu, Feng
    Shirani, Afsaneh
    Oger, Joel
    Freedman, Mark S.
    Tremlett, Helen
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 (03) : 456 - 463
  • [10] Measuring disability progression in multiple sclerosis
    Anat Achiron
    Journal of Neurology, 2006, 253 : vi31 - vi36